Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

• Main Authors: S. E. J. van de Berg (Author), P. T. Pelzer (Author), A. J. van der Land (Author), E. Abdrakhmanova (Author), A. Muhammad Ozi (Author), M. Arias (Author), S. Cook-Scalise (Author), G. Dravniece (Author), A. Gebhard (Author), S. Juneja (Author), R. Handayani (Author), D. Kappel (Author), M. Kimerling (Author), I. Koppelaar (Author), S. Malhotra (Author), B. Myrzaliev (Author), B. Nsa (Author), J. Sugiharto (Author), N. Engel (Author), C. Mulder (Author), S. van den Hof (Author)
• Format: Book
• Published: BMC, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background BPaL, a 6 month oral regimen composed of bedaquiline, pretomanid, and linezolid for treating extensively drug-resistant tuberculosis (XDR-TB) is a potential alternative for at least 20 months of individualized treatment regimens (ITR). The ITR has low tolerability, treatment adhe...